Announcements Trials

Browse Landscape

Phase

Phase 1 11 Phase 2 6 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Multiple Myeloma 2 Melanoma 2 Endometrial Neoplasms 2 Uterine Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Rhabdomyosarcoma 1 Rectal Neoplasms 1 Osteosarcoma 1 Oropharyngeal Neoplasms 1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Neoplasms 1 Mouth Neoplasms 1 Lung Neoplasms 1 Laryngeal Diseases 1 Hodgkin Disease 1 Hepatoblastoma 1 Head and Neck Neoplasms 1 Glioblastoma 1 Fibrolamellar hepatocellular carcinoma 1 Ependymoma 1 Diffuse Intrinsic Pontine Glioma 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Carcinoma 1

Interventions

pembrolizumab 44 Nivolumab 29 Gemcitabine 28 Paclitaxel 19 Cisplatin 18 Ipilimumab 15 Carboplatin 14 Cyclophosphamide 13 Capecitabine 12 Dexamethasone 10 Bevacizumab 10 cemiplimab 9 Irinotecan 9 Docetaxel 9 Albumin-Bound Paclitaxel 9 130-nm albumin-bound paclitaxel 9 spartalizumab 8 Pemetrexed 8 Sorafenib 7 Rituximab 7 Cetuximab 7 fludarabine 6 Temozolomide 6 Taxes 6 Radiotherapy 6 Leucovorin 6 Fluorouracil 6 Azacitidine 6 Ascorbic Acid 6 lenvatinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasms × dostarlimab × Clear all

NCT06796907 2026-05-22

BEHOLD-2

GlaxoSmithKline

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡